Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
48 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07402915 | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 |
| NCT04577833 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | active not recruiting | Phase 1 | 136 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | recruiting | Phase 1 | 120 | Biocon Biologics UK PLCINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT07391670 | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab(IMFINZI-subQ) | recruiting | Phase 1 | 40 | AstraZenecaINDUSTRY | 5 | Sep 24, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 429 | GenmabINDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT07160335 | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | active not recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 | 85 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | completed | Phase 1 / Phase 2 | 175 | Agenus Inc.INDUSTRY | 9 | Aug 11, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT04210219 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 7 | Aug 21, 2025 | clinicaltrials |
| NCT04657224 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 75 | Janssen Research & Development, LLCINDUSTRY | 12 | Aug 21, 2025 | clinicaltrials |
| NCT03307629 | Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer | completed | Phase 1 | 25 | Noxopharm LimitedINDUSTRY | 3 | Jul 29, 2025 | clinicaltrials |
| NCT05391022 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | completed | Phase 1 | 35 | Constellation PharmaceuticalsINDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT04740424 | FS222 First in Human Study in Patients With Advanced Malignancies | recruiting | Phase 1 | 260 | invoX Pharma LimitedINDUSTRY | 7 | Jul 1, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | completed | Phase 1 / Phase 2 | 89 | Syndax PharmaceuticalsINDUSTRY | 2 | Dec 4, 2024 | clinicaltrials |
| NCT03994211 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | completed | Phase 1 | 25 | BeiGeneINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT03711604 | Compassionate Use Study of Tenalisib (RP6530) | completed | Phase 1 / Phase 2 | 17 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | May 8, 2024 | clinicaltrials |
| NCT03827070 | Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma(DPTA) | unknown | Phase 1 | 12 | Center Trials & Treatment EuropeNETWORK | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT00481936 | Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | terminated | Phase 1 | 15 | Sesen Bio, Inc.INDUSTRY | 2 | Mar 23, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT02941523 | Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours | completed | Phase 1 / Phase 2 | 19 | Noxopharm LimitedINDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT00462761 | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | completed | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 2 | May 11, 2020 | clinicaltrials |
| NCT01619423 | A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer(PLIANT) | completed | Phase 1 / Phase 2 | 186 | Egetis TherapeuticsINDUSTRY | 8 | Jul 6, 2018 | clinicaltrials |
| NCT02144272 | Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | completed | Phase 1 | 41 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 17, 2015 | clinicaltrials |
| NCT00364754 | Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer | completed | Phase 1 | 28 | YM BioSciencesINDUSTRY | 3 | Apr 21, 2014 | clinicaltrials |
Data updated 7 hours agoSource updated unknownsource: clinicaltrials